BioSyent, Inc. (RX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioSyent, Inc.

Knight Therapeutics, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Fennec Pharmaceuticals, Inc.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Arch Biopartners, Inc.

Defence Therapeutics Inc

Cybin, Inc.

Mindset Pharma, Inc.

Why is BioSyent, Inc. ?

High Management Efficiency with a high ROE of 18.15%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50

Positive results in Mar 25

OPERATING CASH FLOW(Y) Highest at CAD 8.92 MM
ROCE(HY) Highest at 22.17%
INTEREST COVERAGE RATIO(Q) Highest at 24,114.96

With ROE of 21.97%, it has a very attractive valuation with a 3.43 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 4.23%, its profits have risen by 15.5% ; the PEG ratio of the company is 0.8

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to BioSyent, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is BioSyent, Inc. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

BioSyent, Inc.

6.22%

6.55

25.00%

S&P/TSX 60

19.1%

1.23

15.27%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.80%

EBIT Growth (5y)

8.45%

EBIT to Interest (avg)

7.50

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.94

Tax Ratio

25.74%

Dividend Payout Ratio

29.49%

Pledged Shares

Institutional Holding

ROCE (avg)

100.69%

ROE (avg)

18.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.43

EV to EBIT

10.78

EV to EBITDA

10.01

EV to Capital Employed

6.25

EV to Sales

2.76

PEG Ratio

0.83

Dividend Yield

ROCE (Latest)

57.94%

ROE (Latest)

21.97%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 8.92 MM

ROCE(HY)

Highest at 22.17%

INTEREST COVERAGE RATIO(Q)

Highest at 24,114.96

INVENTORY TURNOVER RATIO(HY)

Highest at 1.62%

DIVIDEND PER SHARE(HY)

Highest at CAD 9.17

NET SALES(Q)

Highest at CAD 10.98 MM

OPERATING PROFIT(Q)

Highest at CAD 3.16 MM

PRE-TAX PROFIT(Q)

Highest at CAD 3.16 MM

NET PROFIT(Q)

Highest at CAD 2.32 MM

EPS(Q)

Highest at CAD 0.2

-2What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 5.13% (YoY

CASH AND EQV(HY)

Lowest at CAD 33.34 MM

Here's what is working for BioSyent, Inc.

Operating Cash Flow

Highest at CAD 8.92 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Interest Coverage Ratio

Highest at 24,114.96

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales

Highest at CAD 10.98 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Net Sales

At CAD 10.98 MM has Grown at 25.36%

over average net sales of the previous four periods of CAD 8.76 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Profit

Highest at CAD 3.16 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Pre-Tax Profit

Highest at CAD 3.16 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CAD MM)

Net Profit

Highest at CAD 2.32 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

EPS

Highest at CAD 0.2

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Inventory Turnover Ratio

Highest at 1.62%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Dividend per share

Highest at CAD 9.17

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (CAD)

Here's what is not working for BioSyent, Inc.

Cash and Eqv

Lowest at CAD 33.34 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 5.13% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales